Safety and Performance of Agilik in CP

Last updated: February 19, 2025
Sponsor: IRCCS Eugenio Medea
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cerebral Palsy

Treatment

standard care

Agilik

Clinical Study ID

NCT05746871
GIP1030
  • Ages 5-17
  • All Genders

Study Summary

The purpose of this post market study is to demonstrate the safety and performance of a powered extension assist (EA) knee ankle foot orthosis (KAFO), or EA-KAFO, in individuals with knee extension deficiency due to cerebral palsy (CP). The EA-KAFO tested in this investigation, whose commercial name is Agilik™, is registered as a Class 1 medical device in the European (EU) Medical Device Regulation (MDR) and with the United States (US) Food and Drugs Administration (FDA). The study will take place in Astrolab at the Istituto Scientifico E. MEDEA - La Nostra Famiglia (IRCCS Medea hereafter). The duration of the investigation will be 36 months. The duration of the study for a single subject will be approximately 10 weeks.

The primary purpose of this study is to demonstrate the safety and performance of a powered extension assist knee ankle foot orthosis (Agilik) in individuals with knee extension deficiency due to cerebral palsy. The focus is on the improvement of anti-gravity knee extension during stance in patients with CP with crouch gait. Therefore, the primary aim is to compare the knee and range of motion (ROM) at baseline and after 10 sessions of Agilik training while wearing Agilik itself. Secondary aim is to compare knee ROM before and after the training with Agilik without wearing Agilik.

The changes in lower extremity functions, kinematics and muscle activity during walking with Agilik compared to baseline conditions will be examined. Furthermore, the performance of Agilik during uphill and downhill walking over the GRAIL platform will be investigated.

Hypotheses when using Agilik:

  • Improve knee extension during stance and swing gait phases

  • Increase step length, walking distance and speed

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed and dated informed consent form.

  • Stated willingness to comply with all study procedures and availability for theduration of the study, or alternatively, ability to do so based on parent report andphysician observation during history and physical examination.

  • Age between 5 and 17

  • Maximum weight of 70 Kg

  • Volunteer who have a gait pathology involving the knee joint, from a diagnosis of CP

  • Knee flexion retraction assessed in supine position by less than 10°. Hamstringcontracture as assessed by straight leg raising test does not limit ability toparticipate in the study.

  • Subjects must not have had a tibio-tarsal arthrodesis. In addition, they must haveat least 10° of passive dorsi-flexion of the ankle.

  • Able to walk at least 3 m without stopping with or without a walking aid.

  • Able to understand and follow simple directions based on parent report and physicianobservation during history and physical examination.

  • GMFCS level I, II and III

  • MAS score ≤ 2

Exclusion

Exclusion Criteria:

  • Any neurological, musculoskeletal or cardiorespiratory injury, health condition, ordiagnosis other than cerebral palsy that would affect the ability to walk asdirected for short periods of time.

  • A history of uncontrolled seizure in the past year

  • Severe spasticity

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: standard care
Phase:
Study Start date:
March 02, 2023
Estimated Completion Date:
March 31, 2026

Connect with a study center

  • IRCCS Medea

    Bosisio Parini,
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.